This Educational Series focusses on biologics and biosimilars in cancer treatment.
It examines differences in treatments, registration requirements, interchangeability and switching considerations, and local and international guidelines.
Commentary has been provided by Associate Professor Andy Redfern from the University of Western Australia and Consultant Medical Oncologist at the Fiona Stanley Hospital, Perth.
Please login below to download this issue (PDF)